Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, Coherus Oncology Inc (NASDAQ: CHRS) closed at $1.55 down -3.13% from its previous closing price of $1.6. In other words, the price has decreased by -$3.13 from its previous closing price. On the day, 1.59 million shares were traded. CHRS stock price reached its highest trading level at $1.59 during the session, while it also had its lowest trading level at $1.39.
Ratios:
For a deeper understanding of Coherus Oncology Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.43 and its Current Ratio is at 1.44. In the meantime, Its Debt-to-Equity ratio is 0.45 whereas as Long-Term Debt/Eq ratio is at 0.44.
On August 16, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $4 to $1.50.
On November 17, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $11.Robert W. Baird initiated its Outperform rating on November 17, 2023, with a $11 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 23 ’25 when Wahlstrom Mats sold 99,988 shares for $0.74 per share. The transaction valued at 73,881 led to the insider holds 0 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CHRS now has a Market Capitalization of 180152272 and an Enterprise Value of -16455724. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.26 while its Price-to-Book (P/B) ratio in mrq is 1.50. Its current Enterprise Value per Revenue stands at -0.06 whereas that against EBITDA is 0.196.
Stock Price History:
The Beta on a monthly basis for CHRS is 0.94, which has changed by 1.2099447 over the last 52 weeks, in comparison to a change of 0.15566266 over the same period for the S&P500. Over the past 52 weeks, CHRS has reached a high of $2.43, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is 1.00%, while the 200-Day Moving Average is calculated to be 41.14%.
Shares Statistics:
For the past three months, CHRS has traded an average of 1.22M shares per day and 878790 over the past ten days. A total of 116.22M shares are outstanding, with a floating share count of 105.83M. Insiders hold about 8.94% of the company’s shares, while institutions hold 46.57% stake in the company. Shares short for CHRS as of 1760486400 were 30165888 with a Short Ratio of 24.66, compared to 1757894400 on 31866663. Therefore, it implies a Short% of Shares Outstanding of 30165888 and a Short% of Float of 26.99.
Earnings Estimates
The market rating of Coherus Oncology Inc (CHRS) is currently shaped by the ongoing analysis conducted by 2.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.12 and low estimates of -$0.3.
Analysts are recommending an EPS of between -$1.31 and -$1.31 for the fiscal current year, implying an average EPS of -$1.31. EPS for the following year is -$0.79, with 2.0 analysts recommending between -$0.44 and -$1.13.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $13.41M this quarter.It ranges from a high estimate of $15M to a low estimate of $12M. As of. The current estimate, Coherus Oncology Inc’s year-ago sales were $70.77MFor the next quarter, 5 analysts are estimating revenue of $15.76M. There is a high estimate of $17.57M for the next quarter, whereas the lowest estimate is $12M.
A total of 4 analysts have provided revenue estimates for CHRS’s current fiscal year. The highest revenue estimate was $49.2M, while the lowest revenue estimate was $42.02M, resulting in an average revenue estimate of $46.27M. In the same quarter a year ago, actual revenue was $266.96MBased on 5 analysts’ estimates, the company’s revenue will be $96.91M in the next fiscal year. The high estimate is $161.64M and the low estimate is $61.94M.
